The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...